Medical Patent News

RSS

Eppendorf initiates import ban against Nanosphere's Verigene and Verigene SP systems

Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

16 Dec 2009

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

StemCells, Inc. announced today that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency (the ability to become any cell in the body, which is the defining attribute of embryonic stem cells), including the reprogramming of cells to create pluripotent stem cells.

16 Dec 2009

Italian patent issued for NPM1 to test patients with AML

Xenomics, Inc., a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issued.

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

NovaDel receives Issue Notification from USPTO for oral spray

NovaDel Pharma Inc., today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

16 Dec 2009

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

UNITAID to launch patent pool for HIV/AIDS drugs by mid-2010

The international drug procurement agency UNITAID on Monday unveiled plans to create a patent pool for HIV/AIDS medications to help increase access to generic versions of newer drugs at lower prices for low- and middle-income countries, Agence France-Presse reports. The patent pool "will create a common space for patent holders to license their technology in exchange for royalties" and is "scheduled to begin operating in mid-2010," AFP reports (12/14).

15 Dec 2009

Patent for novel method of cutting tissue materials for use in implantable devices issued

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced that the United States Patent and Trademark Office has issued patent number 7,594,974 regarding a novel method of cutting tissue materials for use in implantable devices.

15 Dec 2009

Haemonetics alleges continued patent infringement by Fenwal, files a new lawsuit

Haemonetics Corporation announced today that it has filed a new legal action to stop Fenwal Inc.'s continued patent infringement resulting from Fenwal's just released red cell collection kits, using a modified separation chamber. Fenwal allegedly modified its separation chamber to circumvent Haemonetics' patent and the injunction entered by the Court prohibiting Fenwal's continued sale of infringing products after December 1, 2010.

15 Dec 2009

CureDM receives patent allowance for novel islet neogenesis program

CureDM, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering a Human proIslet Peptide (HIP) and methods related to its use and administration for treating type 1 diabetes.

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.

15 Dec 2009

Sword Diagnostics receives patent on improved sensitivity technology for detection of biological organisms

Sword Diagnostics, Inc. is pleased to announce that the United States Patent Office (USPTO) has issued patent number 7,599,057 titled "Method and Apparatus for Detection of Biological Organisms using Raman Scattering" to the company.

15 Dec 2009

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.

14 Dec 2009

USPTO grants CyDex Pharmaceuticals patent for Captisol

CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled “Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof.” This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.

9 Dec 2009

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

A depression drug created and patented by a team of University of South Florida researchers is at the center of major deal between global pharmaceutical company AstraZeneca PLC and Targacept, Inc., earning the university its potentially most lucrative patent royalties to date.

9 Dec 2009

ADHC to acquire stem cell patents for commercial purposes

American Diversified Holdings Corporation has announced, as part of its previously disclosed strategy to concentrate in developing innovative technologies in the life sciences sector, specifically targeting the fast growing stem cell arena, that the Company is actively seeking to acquire stem cell patents for the express purpose of developing these patents for commercial purposes.

9 Dec 2009

AbSorber receives patent protection for its XM-ONE in the European countries

AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product.

8 Dec 2009

EPO grants patent for AbSorber's transplantation cross match-test

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

8 Dec 2009

Amino acids can improve cognitive function in patients with severe brain injuries

Neurology researchers have shown that feeding amino acids to brain-injured animals restores their cognitive abilities and may set the stage for the first effective treatment for cognitive impairments suffered by people with traumatic brain injuries.

8 Dec 2009

Medical Patent News

Eppendorf initiates import ban against Nanosphere's Verigene and Verigene SP systems

StemCells receives U.S. patent for propagation and/or derivation of embryonic stem cells

Italian patent issued for NPM1 to test patients with AML

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

NovaDel receives Issue Notification from USPTO for oral spray

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

UNITAID to launch patent pool for HIV/AIDS drugs by mid-2010

Patent for novel method of cutting tissue materials for use in implantable devices issued

Haemonetics alleges continued patent infringement by Fenwal, files a new lawsuit

CureDM receives patent allowance for novel islet neogenesis program

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Sword Diagnostics receives patent on improved sensitivity technology for detection of biological organisms

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

USPTO grants CyDex Pharmaceuticals patent for Captisol

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

ADHC to acquire stem cell patents for commercial purposes

AbSorber receives patent protection for its XM-ONE in the European countries

EPO grants patent for AbSorber's transplantation cross match-test

Amino acids can improve cognitive function in patients with severe brain injuries

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News